IL-1beta, also known as IL1F2, is a prototypical member of the IL-1 superfamily. It is produced by a wide variety of cells in response to inflammatory agents, infections, or microbial endotoxins. The biological activity of IL-1beta is mediated by the heterodimeric receptor complex containing IL-1 R1 (IL-1 RI) and IL-1 R3 (IL-1 RAcP). The IL-1beta propeptide is cleaved intracellularly by caspase-1/ICE to generate a 17kD active cytokine. An alternatively spliced form of equine IL-1beta lacks the caspase-1 cleavage site and is potentially membrane-associated.
Suitable for use in Western Blot and Direct ELISA. Other applications have not been tested.
Western Blot: 1-2ug/ml. The detection limit for recombinant equine IL-1b is ~5ng/lane under non-reducing and reducing conditions. Chemiluminescent detection will increase sensitivity 5 to 50 fold
Direct ELISA: 0.5-1ug/ml. The detection limit for recombinant equine IL-1b is ~2ng/well.
Optimal dilutions to be determined by the researcher.
Produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from rat.
Storage and Stability:
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.